These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25286755)

  • 41. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
    Lu RL; Hu CP; Yang HP; Li YY; Gu QH; Wu L
    Pathol Oncol Res; 2014 Apr; 20(2):445-51. PubMed ID: 24297623
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular alterations of EGFR in small intestinal adenocarcinoma.
    Wang Y; Jiang CQ; Guan J; Yang GF; Yue JQ; Chen HL; Xue JL; Xu ZG; Qian Q; Fan LF
    Int J Colorectal Dis; 2013 Oct; 28(10):1329-35. PubMed ID: 23644682
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by immunohistochemistry.
    Yu X; Mao R; Liu M; Fu L; Shi L; Li X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jan; 46(1):11-17. PubMed ID: 33678631
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry.
    Angulo B; Conde E; Suárez-Gauthier A; Plaza C; Martínez R; Redondo P; Izquierdo E; Rubio-Viqueira B; Paz-Ares L; Hidalgo M; López-Ríos F
    PLoS One; 2012; 7(8):e43842. PubMed ID: 22952784
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma.
    Namba K; Tomida S; Matsubara T; Takahashi Y; Kurihara E; Ogoshi Y; Yoshioka T; Takeda T; Torigoe H; Sato H; Shien K; Yamamoto H; Soh J; Tsukuda K; Toyooka S
    BMC Cancer; 2019 Feb; 19(1):175. PubMed ID: 30808329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer.
    Vora HH; Patel NA; Thakore PM; Shukla SN
    Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):653-60. PubMed ID: 25789532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence and characteristics of Epidermal Growth Factor Receptor (EGFR) mutation in non-small-cell lung cancer (Adenocarcinoma histology): A report of 106 patients from Kolkata.
    Chatterjee K; Ray A; Chattopadhyay B
    Indian J Cancer; 2017; 54(1):305-307. PubMed ID: 29199710
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study.
    Jain D; Iqbal S; Walia R; Malik P; Cyriac S; Mathur SR; Sharma MC; Madan K; Mohan A; Bhalla A; Pathy S; Kumar L; Guleria R
    Indian J Med Res; 2016 Mar; 143(3):308-14. PubMed ID: 27241644
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma.
    Soma S; Tsuta K; Takano T; Hatanaka Y; Yoshida A; Suzuki K; Asamura H; Tsuda H
    Pathol Res Pract; 2014 Mar; 210(3):155-60. PubMed ID: 24355440
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual surrogate markers for rapid prediction of epidermal growth factor receptor mutation status in advanced adenocarcinoma of the lung: A novel approach in resource-limited setting.
    Udupa KS; Rajendranath R; Sagar TG; Sundersingh S; Joseph T
    Indian J Cancer; 2015; 52(3):266-8. PubMed ID: 26905105
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
    Pinter F; Papay J; Almasi A; Sapi Z; Szabo E; Kanya M; Tamasi A; Jori B; Varkondi E; Moldvay J; Szondy K; Keri G; Dominici M; Conte P; Eckhardt S; Kopper L; Schwab R; Petak I
    J Mol Diagn; 2008 Mar; 10(2):160-8. PubMed ID: 18258923
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
    Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
    Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
    Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel use for an EGFR mutation-specific antibody in discriminating lung adenocarcinoma from reactive pneumocyte hyperplasia.
    Mimori T; Kobayashi S; Tanaka A; Sasada S; Yoshida A; Izumo T; Sasaki N; Tsuchida T; Tsuta K
    Histopathology; 2015 May; 66(6):816-23. PubMed ID: 25066097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations.
    Vliegen L; Dooms C; De Kelver W; Verbeken E; Vansteenkiste J; Vandenberghe P
    Diagn Pathol; 2015 May; 10():57. PubMed ID: 26022577
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of EGFR mutation of pulmonary adenocarcinoma in sputum using droplet digital PCR.
    Isaka T; Yokose T; Ito H; Nakayama H; Miyagi Y; Saito H; Masuda M
    BMC Pulm Med; 2021 Mar; 21(1):100. PubMed ID: 33757469
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
    Villa C; Cagle PT; Johnson M; Patel JD; Yeldandi AV; Raj R; DeCamp MM; Raparia K
    Arch Pathol Lab Med; 2014 Oct; 138(10):1353-7. PubMed ID: 24571650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients.
    Hashida S; Soh J; Toyooka S; Tanaka T; Furukawa M; Shien K; Yamamoto H; Asano H; Tsukuda K; Hagiwara K; Miyoshi S
    Oncol Rep; 2014 Jul; 32(1):145-52. PubMed ID: 24842519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidermal growth factor receptor mutations in adenocarcinoma in situ and minimally invasive adenocarcinoma detected using mutation-specific monoclonal antibodies.
    Nakamura H; Koizumi H; Kimura H; Marushima H; Saji H; Takagi M
    Lung Cancer; 2016 Sep; 99():143-7. PubMed ID: 27565930
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epidermal growth factor receptor mutations in adenocarcinoma lung: Comparison of techniques for mutation detection.
    Shukla S; Pandey RK; Mishra S; Tripathi S; Garg R; Gupta G; Husain N
    Indian J Pathol Microbiol; 2022; 65(2):296-304. PubMed ID: 35435362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.